CareRx 配当と自社株買い
配当金 基準チェック /36
CareRxは配当を支払う会社で、現在の利回りは2.52%ですが、利益によって十分にカバーされています。次の支払い日は 8th October, 2026で、権利落ち日は15th September, 2026 。
主要情報
2.5%
配当利回り
1.1%
バイバック利回り
| 総株主利回り | 3.6% |
| 将来の配当利回り | n/a |
| 配当成長 | n/a |
| 次回配当支払日 | 08 Oct 26 |
| 配当落ち日 | 15 Sep 26 |
| 一株当たり配当金 | n/a |
| 配当性向 | 19% |
最近の配当と自社株買いの更新
Recent updates
分析記事 • Aug 01
Earnings Miss: CareRx Corporation Missed EPS By 60% And Analysts Are Revising Their Forecasts
It's been a good week for CareRx Corporation ( TSE:CRRX ) shareholders, because the company has just released its...
ナラティブ更新 • Jun 16
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.
ナラティブ更新 • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.ナラティブ更新 • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).ナラティブ更新 • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.ナラティブ更新 • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).ナラティブ更新 • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).ナラティブ更新 • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.ナラティブ更新 • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.ナラティブ更新 • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.ナラティブ更新 • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.ナラティブ更新 • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).ナラティブ更新 • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.ナラティブ更新 • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.ナラティブ更新 • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.分析記事 • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
新しいナラティブ • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.分析記事 • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...分析記事 • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...分析記事 • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...分析記事 • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...分析記事 • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...配当金の支払いについて
決済の安定と成長
配当データの取得
安定した配当: CRRXは配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。
増加する配当: CRRXは配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。
配当利回り対市場
| CareRx 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (CRRX) | 2.5% |
| 市場下位25% (CA) | 1.5% |
| 市場トップ25% (CA) | 5.6% |
| 業界平均 (Consumer Retailing) | 1.2% |
| アナリスト予想 (CRRX) (最長3年) | n/a |
注目すべき配当: CRRXの配当金 ( 2.52% ) はCanadian市場の配当金支払者の下位 25% ( 1.48% ) よりも高くなっています。
高配当: CRRXの配当金 ( 2.52% ) はCanadian市場の配当金支払者の上位 25% ( 5.62% ) と比較すると低いです。
株主への利益配当
収益カバレッジ: CRRXは低い 配当性向 ( 18.8% ) であるため、配当金の支払いは利益によって十分にカバーされます。
株主配当金
キャッシュフローカバレッジ: CRRXは低い 現金配当性向 ( 23.9% ) であるため、配当金の支払いはキャッシュフローによって十分にカバーされています。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/24 16:17 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
CareRx Corporation 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |